Clinical trialUNITERAREYesterday
New Recruiting Trial: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Novartis is looking for adults who have immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) — two blood disorders where the immune system attacks blood cells — and who previously did well on a drug called ianalumab. This new study will test whether ianalumab continues to work for these patients. The trial is expected to start in April 2026.
WHY IT MATTERSThis trial is recruiting adults who previously responded to ianalumab for ITP or wAIHA, offering a potential path to continued access for patients whose symptoms improved on this treatment.